ZILXI Drug Patent Profile
✉ Email this page to a colleague
When do Zilxi patents expire, and what generic alternatives are available?
Zilxi is a drug marketed by Journey and is included in one NDA. There are eight patents protecting this drug and one Paragraph IV challenge.
This drug has twenty-two patent family members in ten countries.
The generic ingredient in ZILXI is minocycline hydrochloride. There are fifteen drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Zilxi
A generic version of ZILXI was approved as minocycline hydrochloride by WATSON LABS on December 30th, 1991.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ZILXI?
- What are the global sales for ZILXI?
- What is Average Wholesale Price for ZILXI?
Summary for ZILXI
| International Patents: | 22 |
| US Patents: | 8 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 95 |
| Patent Applications: | 2,826 |
| Drug Prices: | Drug price information for ZILXI |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ZILXI |
| What excipients (inactive ingredients) are in ZILXI? | ZILXI excipients list |
| DailyMed Link: | ZILXI at DailyMed |
Pharmacology for ZILXI
| Drug Class | Tetracycline-class Drug |
| Physiological Effect | Decreased Prothrombin Activity |
Paragraph IV (Patent) Challenges for ZILXI
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ZILXI | Topical Aerosol Foam | minocycline hydrochloride | 1.50% | 213690 | 1 | 2022-02-28 |
US Patents and Regulatory Information for ZILXI
ZILXI is protected by eight US patents.
Patents protecting ZILXI
Topical tetracycline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Compositions, gels and foams with rheology modulators and uses thereof
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Topical tetracycline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Topical tetracycline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Topical tetracycline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
Topical tetracycline compositions
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF INFLAMMATORY LESIONS OF ROSACEA.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Journey | ZILXI | minocycline hydrochloride | AEROSOL, FOAM;TOPICAL | 213690-001 | May 28, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Journey | ZILXI | minocycline hydrochloride | AEROSOL, FOAM;TOPICAL | 213690-001 | May 28, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Journey | ZILXI | minocycline hydrochloride | AEROSOL, FOAM;TOPICAL | 213690-001 | May 28, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Journey | ZILXI | minocycline hydrochloride | AEROSOL, FOAM;TOPICAL | 213690-001 | May 28, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Journey | ZILXI | minocycline hydrochloride | AEROSOL, FOAM;TOPICAL | 213690-001 | May 28, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Journey | ZILXI | minocycline hydrochloride | AEROSOL, FOAM;TOPICAL | 213690-001 | May 28, 2020 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for ZILXI
See the table below for patents covering ZILXI around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 2482788 | COMPOSITIONS DE TÉTRACYCLINE À USAGE TOPIQUE (TOPICAL TETRACYCLINE COMPOSITIONS) | ⤷ Sign Up |
| Mexico | 2012003985 | COMPOSICIONES TOPICAS TETRACICLINA. (TOPICAL TETRACYCLINE COMPOSITIONS.) | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2011039637 | ⤷ Sign Up | |
| Canada | 2776366 | COMPOSITIONS MOUSSANTES SANS EAU ET SANS SURFACTANT, MOUSSES ET GELS FRIABLES, AINSI QUE LEURS UTILISATIONS (SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES) | ⤷ Sign Up |
| Australia | 2015224534 | SURFACTANT-FREE WATER-FREE FOAMABLE COMPOSITIONS, BREAKABLE FOAMS AND GELS AND THEIR USES | ⤷ Sign Up |
| World Intellectual Property Organization (WIPO) | 2013136192 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
